Concepedia

Paul Rogers

PR

23

Publications

1.9K

Citations

19

H-Index

1995

Active since

Affiliations

Imperial College London(Current)

Institute of Cancer Research

St George's, University of London

NIHR Imperial Biomedical Research Centre

Acuitas Therapeutics (Canada)

Paul Rogers is an author at Imperial College London specializing in medicine, immunology, and oncology.

ORCID

Top concepts

Publications per year

1995–2023

23

Publications

23

Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice

Paul F. McKay, Kai Hu, Anna K. Blakney et al. · Nature Communications · 2020 · 460 citations · Full text

DT-Diaphorase Expression and Tumor Cell Sensitivity to 17-Allylamino,17-demethoxygeldanamycin, an Inhibitor of Heat Shock Protein 90

LR Kelland, Swee Y. Sharp, Paul Rogers et al. · JNCI Journal of the National Cancer Institute · 1999 · 350 citations · Full text

Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial

Katrina M. Pollock, Hannah M. Cheeseman, Alexander J. Szubert et al. · EClinicalMedicine · 2022 · 149 citations · Full text

<i>In vitro</i> and <i>In vivo</i> Pharmacokinetic-Pharmacodynamic Relationships for the Trisubstituted Aminopurine Cyclin-Dependent Kinase Inhibitors Olomoucine, Bohemine and CYC202

Florence I. Raynaud, Steven R. Whittaker, Peter M. Fischer et al. · Clinical Cancer Research · 2005 · 129 citations · Full text

Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines

Anna K. Blakney, Paul F. McKay, Kai Hu et al. · Journal of Controlled Release · 2021 · 125 citations · Full text

, , +15

Rows per page

1–5 of 23